Drug Information

Drug General Information
Drug ID
D0N0DU
Former ID
DIB012487
Drug Name
DS-6051
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [524973]
Target and Pathway
Target(s) Neurotrophic tyrosine kinase receptor 1 Target Info Inhibitor [550518]
ROS1 Target Info Inhibitor [532994], [550518]
KEGG Pathway MAPK signaling pathway
Endocytosis
Apoptosis
Neurotrophin signaling pathway
Inflammatory mediator regulation of TRP channels
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancer
Central carbon metabolism in cancer
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Neurotrophic factor-mediated Trk receptor signaling
Reactome Frs2-mediated activation
ARMS-mediated activation
NGF-independant TRKA activation
PI3K/AKT activation
WikiPathways MAPK Signaling Pathway
BDNF signaling pathway
Integrated Pancreatic Cancer Pathway
NGF signalling via TRKA from the plasma membraneWP2431:Spinal Cord Injury
References
Ref 524973ClinicalTrials.gov (NCT02279433) A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b. U.S. National Institutes of Health.
Ref 532994ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul;12(7):429-39.
Ref 550518National Cancer Institute Drug Dictionary (drug id 766123).

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.